Analysts/Institutional Investor Meet/Con. Call Updates

Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423 CIN : L24234KA1978PLC003417 www.biocon.com BIO/SECL/TG/2026-27/58 August 11, 2026 To, To, The Secretary The Secretary BSE Limited National Stock Exchange of India Limited Department of Corporate Services Corporate Communication Department Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra Kurla Complex Dalal Street, Mumbai – 400 001 Mumbai – 400 051 Scrip Code- 532523 Scrip Symbol- BIOCON Dear Sir/Madam, Subject: Transcript of Earnings Call Q1 FY27 This is further to our earlier letter dated August 06, 2026, regarding the presentation of Q1 FY27 Earnings Call held on August 06, 2026, please find enclosed herewith the Transcript of the Earnings Call. The same is also available on the website of the Company at https://www.biocon.com/investor- relations/financial-information/earning-call-transcripts/. Kindly take the above information on record. Thanking You, Yours faithfully, For Biocon Limited Rajesh U. Shanoy Company Secretary and Compliance officer ICSI Membership Number: A16328 Biocon Limited Q1 FY27 Earnings Conference Call Transcript August 06th, 2026 Speakers and Participants from Biocon Limited Dr. Kiran Mazumdar Shaw – Executive Chairperson, Biocon Group Mr. Shreehas Tambe – Chief Executive Officer & Managing Director, Biocon Limited Mr. Kedar Upadhye – Chief Financial Officer, Biocon Limited Mr. Anuj Goel – Chief Development Officer, Biocon Limited Mr. Matthew Erick – Chief Commercial Officer – Advanced Markets, Biocon Limited Ms. Rhonda Duffy – Chief Operating Officer, Biocon Limited Mr. Susheel Umesh – Chief Commercial Officer – Emerging Markets, Biocon Limited Mr. Amit Kaptain – Head - Global API Commercials & FDF – EM, Biocon Limited Mr. Siddharth Mittal – Chief Executive Officer & Managing Director, Syngene International Mr. Deepak Jain – Chief Finance Officer, Syngene International Mr. Prashant Nair – Head Investor Relations, Biocon Limited External Participants during Q&A session Sidharth Negandhi – CWC Advisors Neha Manpuria – Bank of America Securities India Limited Surya Patra – Phillip Capital (India) Private Limited Shyam Srinivasan – Goldman Sachs India Securities Private Limited Damyanti Kerai – HSBC Securities and Capital Markets (India) Private Limited Ankit Shah – Canara Robeco AMC Chinni S – Individual Investor Vipulkumar Shah – Sumangal Investments Prepared Remarks Session Moderator: Ladies and gentlemen, good day, and welcome to Biocon Limited Q1 FY27 Earnings Conference Call. As a reminder, all participant lines will be in the listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Please note that this meeting is being recorded. I now hand the conference over to Mr. Prashant Nair, Head Investor Relations, Biocon Limited. Thank you, and over to you, sir. Prashant Nair: Thank you, Neerav. And good morning, everyone. Thank you for joining us today to discuss Biocon's first quarter results for Financial Year 2027. A press release and presentation related to the same have been sent to the exchanges and are uploaded on our website for your reference. Let me introduce the management team on this call. We are joined by Biocon Chairperson, Dr. Kiran Mazumdar- Shaw; Mr. Shreehas Tambe, CEO and Managing Director; Mr. Kedar Upadhye, CFO; along with other senior members of our management team. We will begin with opening remarks from Kiran, following which we will open the call for questions. Please note that this call is being recorded. The recording will be made available on our website within a day, and the call transcript will be shared shortly thereafter. Before we begin, I want to remind everyone about the Safe Harbor related to today's call. Comments made during the call may be forward-looking in nature and must be viewed in relation to the risks that our business faces that could cause our future results, performance, or achievements to differ significantly from what is expressed or implied by such forward-looking statements. Now I would like to hand over the call to Kiran for her opening remarks. Over to you, Kiran. Kiran Mazumdar Shaw: Thank you, Prashant, and a very good morning to everyone. I want to start on a confident note by saying that Biocon is now operating from a position of significant strategic and financial strength. The successful integration of our biosimilars and generics businesses has strengthened our operating model, expanded our global reach, and enhanced our ability to serve patients, customers, and partners across markets. With the major integration and investment phase largely behind us, we are increasingly focused on translating our capabilities into accelerated growth. In addition to which, we are focusing on improved profitability, stronger cash generation, and of course, better returns on capital. Against this backdrop, let me begin with a perspective on the key geographies in which we operate and the opportunities we see across our businesses. North America North America is our largest and most strategically important market and continues to offer significant long-term opportunities across both biosimilars and generics. The policy dialogue is increasingly centred around affordability, patient access, and healthcare sustainability, creating a favourable backdrop for high-quality, cost-effective therapies. We are particularly encouraged by recent legislative and regulatory initiatives aimed at simplifying biosimilar development and removing unnecessary barriers to adoption. As an active participant in these discussions through industry forums and advocacy efforts, we believe that these developments have the potential to further strengthen the long-term outlook for biosimilars in the US. We continue to strengthen our position in the region through the successful commercialization of Bosaya™ and Aukelso™, which is our biosimilar denosumab, Yesafili™, which is our biosimilar aflibercept, and gliraglutide in the US. These launches expand our presence across important and growing therapeutic segments while further enhancing the breadth of our portfolio. At the same time, we continue to strengthen our regional supply network through a combination of our global manufacturing footprint, local manufacturing capabilities, and strategic partnerships, enabling greater proximity to customers and enhancing supply resilience. Together with a favourable policy environment for biosimilars, these developments reinforce our confidence in the long-term opportunities across the North American market. Europe When it comes to Europe, this represents one of the world's most established markets for biosimilars and generic medicines, where healthcare systems increasingly rely on affordable therapies to improve patient access and support long-term sustainability. Following the integration of our product businesses, we now offer a combined portfolio of 11 biosimilars and 8 generic medicines. These span key therapeutic areas supported by tailored commercial strategies across both retail and tender channels. During the quarter, we launched our denosumab biosimilar for bone health across multiple European markets and Abevmy™, our bevacizumab biosimilar, in the Czech Republic and Switzerland. We also expanded our commercial footprint through strategic partnerships in markets such as France, Portugal, Slovenia and Spain, further strengthening market access and positioning the business for future growth. Emerging Markets Emerging markets continue to represent an important growth opportunity for Biocon, driven by increasing healthcare access, rising adoption of biologics and the growing need for affordable therapies. Following the integration of our businesses, we now offer a broader portfolio supported by expanded commercial capabilities and regional partnerships. We are also strengthening regional supply networks through a combination of local partnerships, contra [Showing first 8,000 characters — download PDF for full document]